Abstract
Background Seasonal influenza causes an estimated 100,000–710,000 hospitalizations annually in the United States (U.S.). Treatment with antiviral medications, such as oseltamivir, can reduce risks of hospitalization among people with influenza-associated illness. The U.S. Centers for Disease Control and Prevention recommends initiating antiviral treatment as soon as possible for outpatients with suspected or confirmed influenza who have severe or progressive illness or are at higher risk of influenza complications.
Methods We developed a probabilistic model to estimate the impact of antiviral treatment in reducing hospitalizations among U.S. outpatients with influenza. Parameters were informed by seasonal influenza surveillance platforms and stratified by age group and whether individuals had a medical condition associated with higher risk of influenza complications. We modeled different scenarios for influenza antiviral effectiveness and outpatient testing and prescribing practices, then compared our results to a baseline scenario in which antivirals were not used.
Results Across the modeled scenarios, antiviral treatment resulted in 1,215–14,184 fewer influenza-associated hospitalizations on average compared to the baseline scenario (a 0.2%–2.7% reduction). The greatest effects occurred among adults ≥65 years and individuals with conditions associated with higher risk of influenza complications. Modeling 50% improvements in access to care, testing, prescribing, and treatment resulted in greater potential impacts, with over 71,000 (13.3%) influenza-associated hospitalizations averted on average compared to baseline.
Conclusions Our results support recommendations to prioritize outpatient antiviral treatment among older adults and others at higher risk of influenza complications. Improving access to prompt testing and treatment among outpatients with suspected influenza could reduce hospitalizations substantially.
Summary We probabilistically modeled influenza antiviral treatment among outpatients with influenza virus infection in the United States. Antiviral treatment reduced influenza-associated hospitalizations, with the greatest impacts among adults ≥65 years and persons with conditions associated with higher risk of influenza complications.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
Data Availability
All model inputs and code needed to perform the analysis will be made available at https://github.com/CDCgov upon publication. Data were used solely to inform model inputs and were the result of secondary analyses; the original sources are cited in the text.
